findmyKOL

James Krings, MD

Enriched profile

Assistant Professor of Medicine, Division of Pulmonary and Critical Care · Washington University in St. Louis

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Saint Louis, MO · Midwest · United StatesSpecialtyPulmonary DiseaseFocusAsthma and respiratory diseases+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2024–2026

James Krings is Assistant Professor of Medicine, Division of Pulmonary and Critical Care at Washington University in St. Louis. OpenAlex indexes 75 publications with 1,184 citations (h-index 14); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.

Data verified 19 Oct 2026

Overview

Updated 19 Oct 2026

James Krings, MD, is Assistant Professor of Medicine, Division of Pulmonary and Critical Care at Washington University in St. Louis. The public record shows 75 publications with 1,184 citations (h-index 14), centered on Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, Clinical practice guidelines implementation. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 12 companies, 2 NIH-funded awards (2024–2026).

  • Top research focus: Asthma and respiratory diseases
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 19 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Asthma3 trialsCOPD

Research focus

OpenAlex concept fingerprint
Asthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) ResearchClinical practice guidelines implementationInhalation and Respiratory Drug DeliveryHealth Policy Implementation Science

Drugs & molecules

across trials, industry payments and publications
Pulmicortgeneric · BudesonideClinical trials—Industry payments1Publications1Dupixentgeneric · DupilumabClinical trials—Industry payments32Publications—Xolairgeneric · OmalizumabClinical trials—Industry payments3Publications—Airsuprageneric · Albuterol / budesonideClinical trials—Industry payments2Publications—Fasenrageneric · BenralizumabClinical trials—Industry payments2Publications—AlbuterolClinical trials—Industry payments1Publications—Breztrigeneric · Budesonide / formoterol / glycopyrroniumClinical trials—Industry payments1Publications—Esbrietgeneric · PirfenidoneClinical trials—Industry payments1Publications—Ohtuvayregeneric · EnsifentrineClinical trials—Industry payments1Publications—Pulmozymegeneric · Dornase alfaClinical trials—Industry payments1Publications—Symbicortgeneric · Budesonide / formoterolClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trials—Industry payments42AstraZeneca Pharmaceuticals LPClinical trials—Industry payments17Chiesi USA, Inc.Clinical trials—Industry payments6Genentech USA, Inc.Clinical trials—Industry payments6Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments3Teva Pharmaceuticals USA, Inc.Clinical trials—Industry payments2Washington University School of MedicineClinical trials2Industry payments—Aero US IncClinical trials—Industry payments1Edwards Lifesciences CorporationClinical trials—Industry payments1Genentech, Inc.Clinical trials—Industry payments1GlaxoSmithKlineClinical trials1Industry payments—La Jolla Pharmaceutical CompanyClinical trials—Industry payments1Sanofi-Aventis U.S. LLCClinical trials—Industry payments1Verona Pharma, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
75publications

Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.

1,184citations

Total citations across indexed works.

14h-index

Hirsch index (OpenAlex). i10-index 18.

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials ↓
12companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2024–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 19 Oct 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 19 Oct 2026

12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    77.1%
    Corticosteroid51.2%
    Trelegy Ellipta24%Breztri Aerosphere24%Budesonide-Formoterol Fumarate16%Symbicort14%Fluticasone Propionate12%Breyna6%Dulera5%
    Part D<11 patients
    beta2-Adrenergic Agonist12%
    Albuterol Sulfate Hfa100%
    Part D≥24 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    12.5%
    Corticosteroid7.1%
    Prednisone100%
    Part D≥20 patients
    Proton pump inhibitor5.4%
    Pantoprazole Sodium62%Omeprazole38%
    Part D<11 patients
  • Dermatology

    7%
    Interleukin-4 Receptor alpha Antagonist7%
    Dupixent Pen100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)68.2% facility · 31.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 19 Oct 2026

2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Network

Updated 19 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Mario Castro24Kaharu Sumino12Mary Clare McGregor11Charles W. Goss10Jonathan S. Boomer9Dorina Kallogjeri8Sally E. Wenzel8Loren C. Denlinger7Elliot Israel7Mark D. Huffman7Maanasi Samant7Abigail R. Barker7John V. Fahy6Leonard B. Bacharier6Daphne Lew6Samuel Peterson6Ajay Sheshadri6Amber K. Clover6Eric A. Hoffman5Julia Peled5Kaitlyn M. Wojcik5Shria Bucha5Abigail Zulich5Suzanne M. Simkovich5Eric J. Lenze5Ross C. Brownson5Chase S. Hall5Eliot Jost5Nizar N. Jarjour4Tammy Quinones4Sean B. Fain4Mark L. Schiebler4SERPIL CEM ERZURUM4Jay F. Piccirillo4Joanna L. Buss4Ken B. Schechtman4V. Chen4Bruce David Levy4Jonah M. Graves4George R. Washko4

Online presence

Updated 19 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    broadcastmed.com/pulmonology/5730/videos/asthma-in-2023-time-to-get-smart-finally

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →broadcastmed.com ↗
  • Other

    physicians.wustl.edu/people/james-krings-md-msci

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.wustl.edu ↗
  • Other

    professionals.barnesjewish.org/videos/asthma-in-2023-time-to-get-smart-finally

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →professionals.barnesjewish.org ↗
  • Other

    lung.org/research/about-our-research/meet-the-researchers/james-krings-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lung.org ↗
  • Other

    vumedi.com/video/chest-insights-2024-the-promise-of-biologics-in-copd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vumedi.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 19 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    Scientific Advisory Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lung.org ↗
  • Board Member

    Drug Prior Authorization Committee

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pulmonary.wustl.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.